This implies that abnormal day 3 embryos may undergo a previously un-described normalization process in which day 3 embryos, having a mixture of normal and abnormal cells (mosaicism), undergoes genomic normalization during differentiation to the blastocyst stage. This normalization may be due to the abnormal cells (aneuploid) undergoing degeneration (apoptosis)- there are studies showing there are genes within the embryo that initiate apoptosis in abnormal cells rather than cell division or mitosis, abnormal cells divide less than normal cells thus resulting in their marginalization within the embryos (possibly resulting in fragments seen within the embryo) and /or due to mechanisms within the embryo that are not yet understood.
Initially, Arizona Center for Fertility Studies suggested that all abnormal day 3 embryos, detected by PGD/PGS 23-chromosome microarray, that reached the blastocyst stage by day 5 or day 6 and appeared developmentally normal, should undergo trophectoderm (TE) biopsy, at no additional charge; and than be cryopreserved and if the TE biopsy came back showing a normal chromosome competent; it can be assumed that the embryo had "self-corrected" or undergone normalization and could be used for a future frozen embryo transfer (FET).
As a result of our experience over the last several years doing 23-chromosome microarray; and now what seems to be conclusive evidence that embryos can "self-correct", Arizona Center for Fertility Studies strongly recommends only doing biopsies on day 5-6 embryos (blastocysts) using laser-directed TE (trophectoderm) biopsy. This means that after the blastocyst is biopsied, it will undergo cryopreservation and be transferred in a subsequent frozen embryo transfer (FET) the following cycle. Although this means that the couple will need to wait a cycle to do the transfer, there are a number of advantages of doing a TE biopsy as opposed to a day 3 biopsy:
In Arizona Center for Fertility Studies experience, all these advantages collectedly add up to higher success rates when using PGD/PGS, and is the reason Arizona Center for Fertility Studies now strongly recommends only doing TE biopsy, cryopreservation and subsequent next cycle FET on all patients undergoing PGD/PGS. The one exception is in our out of state patients, unless they can make a return trip. Our success rates are still very good with day 3 biopsy but Arizona Center for Fertility Studies would prefer day 5 TE biopsy.
Call us to learn more about PGD/PGS: 23 Chromosome Microarray and the fertility treatments Arizona Center for Fertility Studies offers to patients in Scottsdale, Phoenix, Mesa, Tempe, Gilbert, Chandler, and Glendale Arizona.